Background
Asthma is experienced during the life span of approximately 10% of the population, resulting in morbidity and mortality costing a substantial economic burden on society [1] . The predominant feature of asthma is the discomfort experienced upon breathing in the presence of excessive and inappropriate constriction of the airway smooth muscle (ASM). Although airway inflammation may play an important role in asthma, it is benign in the absence of airway narrowing. The patient is thus predominantly concerned with narrowing of their airways, contributing to an unpleasant increase in the effort required to breathe; in the extreme, this increased effort fails to allow sufficient ventilation, leading to morbidity and even mortality. As such, ASM is ultimately a major target in any management of asthma.
The earliest recorded treatments of asthma included tobacco, indian hemp, sedation (using low doses of chloroform, ether, or opium), ipecacuana, coffee, tea, stramonium lobelia and other less effective agents. These agents express the pharmacological properties of the xanthines, cholinergic blockade, sympathetic stimulation, sedation and direct smooth muscle relaxation. Direct approaches using anti-cholinergics, anti-histamines, anti-leukotrienes, and functional antagonists modulating intracellular signalling pathways (β-agonists and phosphodiesterase inhibitors) followed (section 3.2). These have been used for decades with reasonable success, but patients continue to suffer exacerbations of asthma. Research energies were poured into developing new therapies to treat airway inflammation to prevent rather than treat the active disease. Asthma therapies using immune modulation and anti-inflammatory therapies proved to be so successful that targeting the ASM receded. Better understanding of the mechanisms underlying contraction of ASM is still essential to the management of the active disease. In this manuscript, basic excitation-contraction coupling in ASM is summarized and several new directions to the treatment of abnormal smooth muscle constriction are introduced.
Overview of excitation-contraction coupling
Asthma is characterized by excess reversible constriction and airway hyperresponsiveness (AHR) to a wide variety of spasmogens. Thus, it is essential to understand the mechanisms underlying excitation-contraction coupling of ASM. Contraction is triggered by phosphorylation of myosin. This is catalyzed by Ca 2+ /calmodulin-dependent myosin light chain kinase (MLCK), which in turn is activated as [Ca 2+ ] i is elevated (see Fig. 1 ). Mechanisms intrinsic to the thin filament and Ca 2+ -sensitivity are also involved and have the potential for therapeutic intervention in modulating these basic responses.
Voltage-dependent mechanisms
Excitation-contraction coupling in cardiac, skeletal, vascular and gastrointestinal smooth muscles depends on membrane depolarization resulting in Ca 2+ -entry via voltage-dependent ('L-type') Ca 2+ -channels. As such, Ca 2+ -channel blockers and K + -channel openers are invaluable in controlling cardiac and smooth muscle contractions in hypertension, stroke, myocardial infarction, gastrointestinal motility disorders, etc. [2] [3] [4] . Excitation of ASM is also accompanied by membrane depolarization mediated primarily by Ca 2+ -dependent Cl ---and non-selective cationchannels, as well as activation of large voltage-dependent Ca 2+ -currents. The latter can be sufficient to produce contraction, as indicated by the robust responses evoked by potassium chloride or K + -channel blockers. As such, a natural conclusion would be that Ca 2+ -channel blockers should be useful in the treatment of asthma: however, they are essentially useless in this respect (see section 9.2). 2+ Internally sequestered Ca 2+ plays an important role in agonist-evoked responses in ASM. The sarcoplasmic reticulum (SR) is central to this, acting as a sink to buffer cytosolic [Ca 2+ ] i , as well as providing an agonist-releasable store of Ca 2+ to trigger contractions. Most, if not all, bronchoconstrictor autacoids act through G-protein-coupled receptors to stimulate phospholipase C activity and subsequent generation of IP 3 , which in turn signals the SR to release stored Ca 2+ (Fig. 1) . The mechanisms underlying IP 3 -and ryanodine receptor-mediated release of internal Ca 2+ and re-uptake of Ca 2+ by the Sarcoplasmic/ Endoplasmic Reticulum Ca 2+ -ATPase (SERCA) are well understood, although their relative roles in excitationcontraction coupling may not be. Other aspects of Ca 2+ -handling are very poorly understood, including the mechanism(s) by which the SR is refilled. Greater magnitude of release of Ca 2+ in cells/tissues pretreated with allergen or pro-inflammatory cytokines has been documented [5] [6] [7] . However, there is little correlation between the magnitude of the initial Ca 2+ -spike, which lasts only a few seconds, and the subsequent contractile response which lasts many minutes or hours. Other groups [8] [9] [10] [11] [12] [13] are now focussing their attention on the frequency of repetitive Ca 2+ -spikes following agonist stimulation.
Release of internal Ca
Changes in Ca 2+ -sensitivity ASM cells also possess a myosin light chain phosphatase (MLCP) which dephosphorylates myosin, limiting or reversing airway contraction (see Fig. 1 ). If MLCP activity is down-regulated, net myosin phosphorylation in response to a given change in [Ca 2+ ] i will be enhanced and/or prolonged, resulting in greater contraction: in other words, the Ca 2+ -sensitivity of the contractile apparatus is increased. At least two different signalling pathways have been found to mediate increased Ca 2+ -sensitivity in Bronchoconstrictors act on G-protein coupled receptors coupled to a variety of signalling pathways Figure 1 Bronchoconstrictors act on G-protein coupled receptors coupled to a variety of signalling pathways involving membrane depolarization (blue), release of internal Ca 2+ (green), changes in Ca 2+ -sensitivity (red), and/or thin filament-mediated mechanisms (magenta).
ASM, the first involving diacylglycerol (another second messenger liberated by phospholipase C) and protein kinase C: the latter can phosphorylate CPI-17, which regulates MLCP activity.
The second pathway involves the monomeric G-protein RhoA and its downstream effector molecule Rho-kinase (ROCK). A decade of study in vascular smooth muscle has revealed certain aspects of this signalling cascade (Fig. 2) . Inactive RhoA exists in the cytosol with its prenylated hydrophobic tail inserted into its partner molecule, GDP dissociation inhibitor (RhoGDI). G-protein-coupled receptors, upon binding their respective ligands, activate the heterotrimeric G-protein G 12,13 , which in turn triggers one or more tyrosine kinases (c-Src, FAK, Fyn, etc.) and other signalling molecules, culminating in the activation of a Rho-specific guanine nucleotide exchange factor (RhoGEF). Numerous GEFs have been identified in the human genome, but the ones most studied include LARG, PDZ-RhoGEF and p115 RhoGEF. These displace RhoGDI and stimulate exchange of GDP for GTP, activating RhoA, which translocates to the membrane and interacts with ROCK. The latter in turn phosphorylates MLCP at two different threonine residues [14] -Thr696 (inhibiting its phosphatase activity) and Thr853 (interfering with its targeting of myosin) -ultimately leading to suppression of MLCP activity. RhoA inactivates by hydrolyzing the GTP bound to it (catalyzed by Rho-GTPase activating protein, or RhoGAP) and re-associating with RhoGDI.
Much of the data summarized above were derived from vascular smooth muscle, which may not be applicable to ASM. There are many examples of how these two tissue types can operate quite differently. For example, the two differ dramatically with respect to the role of Ca 2+ /calmodulin-dependent protein kinase II in activation of RhoA [15] . Likewise, both airway and vascular smooth muscle have exactly the same cellular machinery for voltage-dependent contractions, but have diametrically opposite dependence upon that pathway. Very little is known about the regulation of the Rho/ROCK signalling pathway in ASM, but its exploration may provide novel targets for therapeutic intervention.
Thin filament-mediated mechanisms
All of the signalling mechanisms summarized above are directed in one way or another at phosphorylation/ dephosphorylation of myosin (i.e., the "thick filament"). Emerging data now also point to a number of mechanisms pertaining specifically to actin (the "thin filament") [16] . In particular, calponin and caldesmon both interact with F-actin and myosin and inhibit actomyosin ATPase activity. Both are regulated by adrenoceptor-stimulated PKC-and ERK-activities: the latter mediate changes in the phosphorylation state and/or localization of caldesmon and calponin, leading to removal of inhibition of actin, resulting in contraction.
Evolution of asthma therapy
By and large, the advances made in our understanding of excitation-contraction coupling in ASM have been driven largely from other fields, first in skeletal muscle and later vascular smooth muscle, neither of which are good models for ASM physiology (since their physiology is quite different from that of ASM).
Basic pharmacology of excitation of ASM
Knowledge of the innervations of the airway and the response of ASM to circulating hormones initiated current therapies. The excitatory innervation of ASM is parasympathetic, exerting its actions primarily through muscarinic cholinergic receptors [17;18]. Cholinergic receptor blockers progressed from belladonna and stramonium lobeline, leading eventually to atropine. Atropine had substantial side effects, given its pleiotropic effects throughout the body. The inhaled route was exploited to direct treatment to the airway but absorption into the circulation led to distal side effects. Ipratropium bromide, not readily absorbed into the bloodstream, eliminated the major side effects, and is an effective bronchodilator. Anticholinergics, including ipratropium and its long-acting equivalent tiotropium, have been used to treat asthma but in general adrenergic agents are preferred. Anti-cholinergic agents are used with acute severe asthma but are not broadly used in the day-to-day management of mild to Summary of Rho/ROCK signalling cascade Sympathetic stimulation relaxes ASM. The finding that the effects of sympathetic stimulation were mimicked by adrenalin (discovered at the turn of the last millenium) and noradrenalin led to the discovery of chemical neurotransmission. In the 1940's the concept of adrenergic receptor subtypes arose due to the different effects of adrenalin on different tissues. This ultimately led to the discovery of specific agonists causing ASM relaxation (β 2 -receptor agonists). Short-and long-acting β-agonists are now the most widely used bronchodilating agents.
The airways of some species including man exhibit a nonadrenergic, non-cholinergic innervation which make a minor contribution to ASM activity. The agonist for this system is still debated, but may include nitric oxide. As such, nitric oxide may provide a useful target for the treatment of asthma.
Asthma precipitated by allergen exposure in sensitized subjects provides a useful experimental model. Allergen binds to IgE on the surface of mast cells following inhalation leading to the immediate release of histamine, which in turn causes an immediate ("early") bronchoconstrictor response within 10 minutes and lasting approximately 90 minutes. Histamine acts on H 1 receptors on the ASM, which in turn are coupled to the same signalling pathways utilized by muscarinic receptors (namely, activation of the phosphoinositide cascade, release of internally sequestered Ca 2+ and possibly Rho/ROCK-mediated enhancement of Ca 2+ -sensitivity). Anti-histamines have been proven to be partially effective in the treatment of asthma [18] . The early response is followed 6-8 hours later by a second more prolonged bronchoconstriction lasting many hours or even days, mediated in part by a "slow-reacting substance of anaphylaxis", or SRSA [19] . Upon further investigation, leukotrienes proved to be the mysterious SRSA, leading to the award of a Nobel Prize [94] . In addition to their actions on various inflammatory cells (largely mediated by LTB 4 ), leukotrienes act on cys-LT 1 receptors on the ASM: the latter are also G-protein-coupled receptors and, once again, act through stimulation of the phosphoinositide signalling cascade and of the Rho/ROCK-mediated change in Ca 2+ -sensitivity. This led to the development of blockers of those receptors and of leukotriene synthesis (lipoxygenase inhibitors). The efficacy of these agents in the treatment of asthma has been less than that initially expected but these compounds are widely used.
Functional antagonism of a "convergent signalling pathway" in ASM Ironically, the disappointing results of the therapeutic strategies summarized above appear to be due in part to the exceptional pharmacological selectivity of the agents being used. The airways receive numerous excitatory inputs, each acting exclusively on its own distinct plasmalemmal receptor (Fig. 3) , and asthma is accompanied by non-specific AHR to a wide variety of excitatory stimuli. As such, an approach which interrupts the intracellular signalling pathways used by many/all of the excitatory stimuli is an exciting prospect.
It was hoped that one such common pathway was voltagedependent Ca 2+ -influx. The latter is of central importance in cardiac, skeletal, vascular and gastrointestinal muscles, and Ca 2+ -channel blockers are highly useful in many diseases of those tissues [20, 21] . There are many lines of evidence which suggest voltage-dependent Ca 2+ -influx should also be important in ASM, including the depolarizing influence of bronchoconstrictors, the hyperpolarizing influence of bronchodilators, the abundance of the very same type of Ca 2+ -channel as is present in the nonairway muscles listed above, and the substantial contractions evoked in ASM by high millimolar potassium chloride. It was natural, then, to believe that asthma might also be treated using Ca 2+ -channel blockers: however, this approach has proven to be useless [22] [23] [24] [25] [26] [27] [28] . Despite this setback, others went on to test the potential efficacy of K + -channel openers in the treatment of asthma, even though the underlying rationale for such an approach is identical to that of using Ca 2+ -channel blockers (i.e, to hyperpolarize the membrane such that Ca 2+ -channels are deactivated). Not surprisingly, this approach was also found to be completely ineffective [29] [30] [31] [32] . These and many other findings accumulated over decades of research are most simply interpreted as indicating that voltage-dependent Ca 2+ -influx is not centrally important in ASM contraction and asthma. Nonetheless, even today there still appears to be a tacit adherence to the dogma that such electromechanical coupling is important. A better understanding of contraction/relaxation in ASM demands a new emphasis on mechanisms which are independent of membrane potential (see below).
Another major line of research focussed on those stimuli which exert an inhibitory (i.e., relaxant) influence on the ASM. The predominant inhibitory innervation is adrenergic in nature, with the neurotransmitter norepinephrine and circulating catecholamines (particularly epinephrine) acting on β-adrenoceptors (more specifically β 2 -subtype in human and many other species). Binding of these ligands to the β 2 -receptors leads to stimulation of adenylate cyclase, production of cAMP and consequent increase in protein kinase A activity, which in turn mediates many changes that are opposite to those exerted by the bronchoconstrictor agents: vis-a-vis, decreased cytosolic levels of Ca 2+ (through a variety of actions on plasmalemmal K + -and Ca 2+ -channels [33] , as well as the Ca 2+ -pumps on the plasmalemma and the SR [34]), inhibition of the RhoA/ ROCK signalling pathway [35] and direct stimulation of MLCP [34] . A more recent development which builds on the knowledge of the actions of cAMP on ASM has been the application of phosphodiesterase inhibitors in the treatment of asthma. These suppress the hydrolysis of cAMP, allowing greater and more prolonged actions upon adrenergic stimulation.
Anti-inflammatory agents
Given that many of the manifestations of asthma are triggered directly or indirectly by inflammation, asthma treatment is closely allied with immunology. The strategy of interfering with the inflammatory response using an ever longer list of corticosteroids, inhibitors of leukotriene synthesis or leukotriene receptors, blockers of IgE receptors, or of cytokines has been undoubtedly successful. The past decade or two has witnessed a massive research effort to better understand the inflammatory response, with immense resources and energies being directed at identifying newer anti-inflammatory agents. A full description of this body of research is beyond the scope of this communication. Prevention of asthma through these strategies is important but treatment of the acute bronchoconstriction will always be required. "If airway inflammation didn't cause acute bronchoconstriction, asthma might be a more tolerable disease" [36] . The most effective strategy to acutely dilate an airway will always be predicated on understanding the process of excitationcontraction coupling (above) and exploiting those mechanisms. An increasingly familiar experience is inadequate treatment of the airflow limitation associated with asthma.
Novel directions
Despite all the advances summarized above, and the pharmacological interventions which have arisen from them, it still remains that asthma is not well controlled in many individuals. Clearly, different approaches need to be developed. Acetylcholine, histamine and leukotrienes all act through a convergent signalling pathway (Fig. 3) : the same is true for other spasmogens such as endothelin, serotonin, substance P, etc.. Appreciation of this fact allows for several potential novel targets to be explored.
The non-specific nature of airway hyperreactivity and a convergent signalling pathway for spasmogens: hope for a novel therapy for asthma? Figure 3 The non-specific nature of airway hyperreactivity and a convergent signalling pathway for spasmogens: hope for a novel therapy for asthma? ASM receives diverse excitatory inputs from the innervation, inflammatory cells, and the epithelium, all of which act through distinct receptors, but a common signalling pathway. In asthma, the smooth muscle exhibits increased sensitivity to a wide range of excitatory stimuli. The non-specific nature of airway hyperreactivity suggests that some post-receptor mechanism(s) within the smooth muscle per se is altered. Spasmogens act through a convergent signalling pathway involving Ca 2+ -handling and RhoA.
Release of internal Ca 2+
All of the bronchoconstrictor stimuli referred to above act through G-protein-coupled receptors to stimulate Ca 2+ -release. In contrast to the relative impotence of blockers of voltage-dependent Ca 2+ -influx, a long and ever-growing list of in vitro studies of isolated airway tissues attests to the much greater effect of inhibiting IP 3 -induced Ca 2+ -release or of depleting the SR using blockers of SERCA. A major drawback is that this Ca 2+ -homeostatic pathway is central in nearly every cell type in the body, and therefore seems to fail to offer a sufficiently selective target. However, the same criticism can be levelled at many of the other therapeutic approaches which have already been tried (e.g., targeting cAMP). It may be possible to identify components of the Ca 2+ -homeostatic pathway which are specific to ASM, and/or to limit delivery of agents by having patients inhale modulators of this pathway.
Recently, a great deal of attention has been focussed on the mechanisms underlying refilling of the SR. In many cells, depletion of the internal Ca 2+ -store triggers a Ca 2+ -influx pathway. We have begun to characterize a membrane current which is evoked in ASM by depletion of the SR using the SERCA inhibitor cyclopiazonic acid [37] . This current exhibits many electrophysiological and pharmacological properties in common with Ca 2+ store depletion-activated currents in other cell types referred to as TRP (Transient Receptor Potential) currents [38, 39] . Surprisingly, several recent reviews [38,40,41] have highlighted the potential of TRP-channels as therapeutic targets in ASM, despite the fact that there had not yet been any direct electrophysiological data pertaining to TRP currents in ASM: up to that point, the supporting data for these currents had been obtained exclusively from studies using fluorimetric Ca 2+ -dyes (which poorly discriminate Ca 2+ -influx pathways) or very indirect approaches based on mechanical responses as indices of Ca 2+ -handling. In both cases, the studies have relied on the dubious selectivities of a variety of pharmacological tools.
Several groups including our own have published data which suggest voltage-dependent Ca 2+ -channels may also contribute to refilling and maintenance of the SR [42-47]. More surprisingly, our data suggest that this refilling pathway in ASM does not involve SERCA, but some novel interaction of the SR and the plasmalemma which allows Ca 2+ to flow directly from the extracellular space into the SR [42, 43] . Elsewhere, a model has been proposed which describes one such interaction [48] [49] [50] [51] [52] [53] . Briefly, agonistinduced depletion of the internal store triggers activation of protein tyrosine kinases and Ras: these cause the cytoskeleton to re-organize in such a way as to directly couple IP 3 -receptors on the SR with Ca 2+ -channels on the plasmalemma. Several observations made in ASM are consistent with such a mechanism: (i) spasmogenic stimulation of ASM is accompanied by activation of tyrosine kinases [54] [55] [56] and Ras/Rho [57] [58] [59] [60] , as well as cytoskeletal rearrangement [55, [59] [60] [61] ; (ii) tyrosine kinase inhibition compromises SR refilling [62] ; (iii) ASM depleted of FAK (which regulates cytoskeleton stability) shows marked suppression of cholinergic Ca 2+ -transients and contractions as well as changes in voltage-dependent Ca 2+ -channel function, without any disruptive changes in the contractile apparatus per se (assessed by addition of Ca 2+ to permeabilized strips) [63] . However, the possible role for this novel SR refilling pathway has not yet been tested in ASM: its presence and operation in ASM would supply another potential target for the treatment of asthma.
Other groups are calling attention to the temporal dynamics of Ca 2+ -signalling rather than merely the amplitude of the Ca 2+ -responses. That is, they show that excitatory stimuli do not simply trigger a solitary rise and fall of [Ca 2+ ] i , but rather a series of repetitive Ca 2+ "spikes" or "waves". More importantly, their data indicate that the strength of the contractile response evoked by a bronchoconstrictor depends not so much on the absolute peak magnitude of the Ca 2+ -elevation, but rather the frequency of the Ca 2+ waves [64, 65] . As such, it may soon prove possible to modulate airway constriction using agents which modulate Ca 2+ -wave frequency. That is, rather than merely blocking the channels which release internally sequestered Ca 2+ from the SR, it may be possible to modulate the kinetics of their activation, thereby affecting the onset of each Ca 2+ -spike. Alternatively, the cellular effectors which determine the decay or resolution of each Ca 2+ -spike may offer useful targets: these include the Ca 2+ -release channels themselves (perhaps it might be possible to accelerate their deactivation or inactivation), as well as the cellular entities which restore [Ca 2+ ] i to resting levels (the plasmalemmal Ca 2+ -pump, SERCA and Na + /Ca 2+ exchange).
Cl ---channels ASM exhibits large Cl --currents in response to excitatory stimuli, and these are tightly regulated by second messenger signalling events [66] [67] [68] [69] [70] [71] [72] . It is usually concluded that Cl --currents are important for excitation-contraction coupling by depolarizing the membrane and thus triggering voltage-dependent Ca 2+ -influx, and would for this reason provide a potential target for asthma therapy. However, this therapeutic approach should be no more effective than suppressing voltage-dependent Ca 2+ -influx using Ca 2+ -channel blockers or K + -channel openers (neither of which have proven to be effective). Why, then, are Cl ---channels so prominent in ASM?
A Cl ---channel has been isolated from ASM with properties similar to those on the SR of skeletal and cardiac muscle where they facilitate Ca 2+ -flux by neutralizing charge build-up on the SR membranes [73] . We have therefore proposed an entirely novel and testable hypothesis [74] : that agonists activate Cl --currents in ASM in order to facilitate Ca 2+ -release/uptake. That is, Ca 2+ -efflux from the SR leads to a net negative charge on the inner face of the SR membrane which hinders Ca 2+ -release unless alleviated by compensatory fluxes of Cl --out of the SR. Given that the agonists trigger substantial plasmalemmal Cl --currents, the sudden loss of Cl --from the subplasmalemmal space would instantaneously alter the equilibrium potential for Cl --across the SR membrane, thereby facilitating efflux of Cl --(and Ca 2+ ) from the SR. Consistent with this, we found contractions evoked by various stimuli including caffeine to be reduced by removing external Cl -- [75] ; interestingly, reintroduction of Cl --restored the initial peak response, suggesting normal refilling of the SR.
Cytosolic [Cl --] may also modulate RhoA/ROCK signalling in ASM. While characterizing the agonist-evoked Cl ---currents in canine ASM, we noted contractions could be evoked repeatedly during voltage clamp at -60 mV (at which voltage-dependent Ca 2+ -channels are not open) and in the presence of cyclopiazonic acid [43]: such contractions are clearly independent of both voltage-dependent Ca 2+ -influx and release of internal Ca 2+ and therefore likely involve altered Ca 2+ -sensitivity of the contractile apparatus. More importantly, we found that cells which were perfused internally with a Cl ---deficient electrode solution quickly lost the ability to contract [70] . One interpretation of these findings is that Cl --is somehow essential to Rho and/or ROCK activation. Consistent with that, we have found that the Cl ---channel blocker niflumic acid markedly suppresses cholinergically-induced RhoAactivation. Changes in subplasmalemmal [Cl --] might facilitate translocation of RhoA to the membrane, or enhance interactions between the different components of this signalling cascade. Others have shown G-protein activity to be modulated by [Cl --] [76] . Alternatively, it might be possible that changes in cytosolic [Cl --] somehow affect ROCK activation and/or kinetics.
RhoA/ROCK signalling
An ever growing literature attests to the importance of the RhoA/ROCK signalling pathway in increased Ca 2+ -sensitivity of smooth muscle in general. ROCK inhibitors are effective as bronchodilators [35, [77] [78] [79] . Increased RhoA/ ROCK activities have been documented in allergic models of asthma [80] [81] [82] [83] [84] [85] [86] . However, little is known about the details underlying activation and modulation of this signalling pathway in ASM. Work done in vascular smooth muscle, or even non-muscle preparations, may not be equally applicable in ASM, as exemplified in the great deal of time and effort spent, and lost, on studying voltagedependent Ca 2+ -influx in ASM. Also, although many have examined stimulation of the RhoA/ROCK signalling pathway by excitatory agonists [77, 79, [87] [88] [89] [90] , very few have looked at the effects of relaxant agonists on this pathway. Recently, we were the first to measure directly the activities of RhoA and ROCK in ASM using immunoprecipitation pull-down and radiometric enzyme assays [15, 35, 88] , and so documented the kinetics of activation of these two signalling molecules: RhoA becomes activated within seconds, reaching a peak within 2 minutes, but then falls back toward baseline even though tone continues to build. We also described the inhibitory effects, particularly on ROCK activity, of two different β-agonists -isoproterenol (a short-acting, non-selective β-agonist with full agonist activity) and salmeterol (a long-acting, β 2 -selective agonist with only partial agonist activity), both of which signal through stimulation of adenylate cyclase activity -and a nitric oxide donor (S-nitroso-N-acetylpenicillamine; acting through stimulation of guanylate cyclase).
Many of the details underlying RhoA/ROCK activation remain to be explored. We were the first to show in ASM that RhoA is activated by potassium chloride [88] . Follow up work showed that this is directly related to elevated [Ca 2+ ] i , although membrane depolarization per se may also be involved. Changes in ROCK activity parallelled those in RhoA, suggesting KCl is not exerting an additional effect on ROCK (i.e., is only stimulating RhoA). How might Ca 2+ and membrane voltage stimulate RhoA activity? It may be that Rho-activation is Ca 2+ -dependent, although this explanation must explain the relative inefficacy of Ca 2+ -channel blockers. Alternatively, proteins are charged molecules, and those which need to translocate to the membrane must by influenced by the transmembrane voltage gradient. On the other hand, there is a growing literature describing direct physical interactions between various enzymes and ion channels, including "L-type" Ca 2+ -channels [91, 92] . It is possible that depolarizationinduced conformational changes in the channel proteins are transduced to accessory cytosolic proteins including RhoA; Ca 2+ -channel blockers do not necessarily affect those conformational changes, which could explain why ASM is refractory to that class of drug. None of these possibilities have been explored sufficiently.
Finally, the downstream targets which ROCK must phosphorylate to evoke contraction have not been examined in detail. MLCP may be the primary target [93] . However, data from non-airway tissues suggest that ROCK also phosphorylates myosin light chain per se [94, 95] , ezrin/ radixin/moesin family proteins [96] [97] [98] [99] , elongation factor-1α [100] , adducin [99, 101] , intermediate filaments [102] [103] [104] , and LIM-kinase [105, 106] . There likely are other targets which have not yet been revealed. HMG-CoA reductase inhibitors or 'statins' are widely used to normalize hypercholesterolemia [107] . However, it is now becoming clear that their beneficial effects may not only lie in their ability to decrease cholesterol synthesis per se [108] . Geranylgeranylpyrophosphate, an isoprenoid intermediate arising from this biosynthetic pathway, is essential in the activation of RhoA. As such, statins may also act by suppressing Rho/ROCK signalling, a pharmacological action which might be exploited in asthma.
Tyrosine kinase(s)
We have shown the non-specific tyrosine kinase inhibitor genistein to have powerful inhibitory effects on cholinergic responses in ASM [89] . However, the identity of the tyrosine kinase(s) and the target(s) of its stimulation are largely unclear. There is currently a great deal of attention being focussed upon the role(s) of FAK in cholinergic responses in ASM [109] [110] [111] : upon stimulation, FAK can be autophosphorylated on tyrosine 397, recruiting other non-receptor PTKs such as pp60 src and pp59 fyn (via their SH2 domains), which can create additional tyrosine phosphorylation on other residues of FAK. Also, there is reason to believe that tyrosine phosphorylation is part of the RhoA signalling pathway (leading to activation of Rho-GEF) as well as to Ca 2+ -handling in ASM [54] . Thus, tyrosine kinase inhibitors could prove valuable in the treatment of asthma, if a sufficiently selective molecule can be found.
Actomyosin ATPase activity and cross-bridge cycling
Rather than interfering with various "up-stream" signalling events, it could be much more effective to target the penultimate step in excitation-contraction coupling. Activation of actomyosin ATPase activity, through the phosphorylation of myosin light chain, and cross-bridge cycling are the final determinants in the overall cascade of events leading to contraction. A direct inhibitor of MLCK could be far more effective than intervening further upstream using β-agonists and phosphodiesterase inhibitors. On the other hand, MLCP offers a tantalizing target: the identification of a compound which directly, and hopefully selectively, stimulates this activity would be equally effective in the treatment of asthma. In contrast to the extensive literature at hand pertaining to kinases and the availability of innumerable "selective" kinase inhibitors, the phosphatase field is still in its infancy: relatively few selective inhibitors are yet available, perhaps in part because the actual catalytic subunit of these enzymes acts non-selectively on a wide variety of substrates but is brought into proximity of a specific substrate by the targeting subunit. As such, perhaps the targeting subunit should itself be targeted by researchers. Clearly, any putative MLCK inhibitors or MLCP stimulants to be developed for use in asthma would have to contend with the issue of unwanted systemic effects, given the importance of these enzymes in a wide variety of processes and cell types. However, as pointed out above, it may be possible to limit the systemic delivery of any trial compounds by developing them as inhaled agents and/or using gene therapeutic approaches.
The so-called thick filament-mediated mechanismsthose centering around myosin -have eclipsed research in ASM excitation-contraction coupling in large part, and the development of anti-asthma therapies in total. The growing understanding of the importance of thin filamentmediated mechanisms in smooth muscle contraction may eventually reveal other therapeutic approaches for dealing with airway bronchospasm.
Approaches designed to decrease ASM mass per se
A radically different approach would be to ablate the ASM itself, rather than modulate its activity. The question of "why do we have airway smooth muscle" has been raised repeatedly in the past with no convincing and satisfying answers yet (this question is deftly reviewed in ref. [112] ). An exciting new development in this arena has been the controlled delivery of thermal energy to the airways using an intrabronchial catheter: a process now referred to as bronchial thermoplasty [113, 114] . This technique was originally intended to serve as a treatment for chronic obstructive pulmonary disorder, in which collapse of the airways and gas trapping is a major problem: as such, the thought was that inducing scarring of the airways might make them stiffer and thus remain patent. Instead, no scarring is evident and the airways look completely normal except for the peculiar absence of smooth muscle cells; patients also commented on improved lung function and reduction of symptoms related to asthma. Preclinical development-stage work was done in dogs, and included a long series of studies aimed at determining the intensity and duration of delivery of radiofrequency energy required to achieve 50% reduction in ASM mass. The procedure was next tested in a small group of mild asthmatics, and is now being tested in a group of moderate-severe asthmatics. The success of this approach underscores the potential value in developing other means to eradicate the ASM, including the smaller airways. It may be possible to develop toxic chemical interventions which could be delivered specifically to the ASM (e.g., via gene therapeutic approaches). Further studies of the cell cycle of ASM are essential, since it may eventually be possible to inhibit ASM proliferation and/or promote ASM apoptosis, both of which would achieve the same desired goal of decreasing overall ASM muscle mass. Likewise, a better understanding of ASM migration could lead to the development of agents which prevent the hypertrophy/hyperplasia which accompany asthma.
Prospects for the future
As stated above, there have not been any substantially new pharmacological advances in the past decade or two with respect to treatment strategies for asthma which target the ASM. Admittedly, there have been newer β-agonists or phosphodiesterase inhibitors, but these represent only modifications of decades-old strategies. Any truly new advances have been aimed at controlling inflammation, which is also important but should not eclipse any efforts aimed at controlling bronchoconstriction directly. We have stated repeatedly that a better understanding of the mechanisms underlying ASM contraction and AHR is a prerequisite for any such new advances, and that it would be unwise to base any such understanding solely on work being done in the vascular smooth muscle field, let alone others studying non-muscle tissues.
Physiological studies have for too long suffered from important design flaws and limitations. First, the vast majority of studies have been done using tracheal smooth muscle rather than the smaller airways which are far more important in determining resistance to airflow and which are the clinically relevant site of airway inflammation: compounding this shortsightedness is the growing body of literature which shows major structural and functional differences between the large and small airways. Also, too many use maximally effective concentrations of excitatory stimuli -e.g., near millimolar concentrations of cholinergic agonists -even though such degrees of stimulation are rarely (if ever) reached in nature; this problem is exacerbated by numerous studies which suggest the relative contributions of various signalling events can vary over the full range of a concentration-response relationship. Mitchell and Sparrow have elegantly shown that only the lower half of the full concentration-response relationship may be relevant, since complete airway closure can occur at roughly the half-maximally effective concentration [115] . As such, any further increase in tension seen at higher concentrations would be completely occult: thus, we need to focus instead on submaximal or even threshold responses. Related to this point, many are now showing that isotonic recordings (in which the muscle shortens as tone develops) capture information which is unavailable or distorted in isometric studies (the mainstay of most studies of ASM physiology and pharmacology). Finally, the bulk of the data pertaining to this matter were obtained under static conditions, whereas very recent work now shows ASM function to be powerfully modulated by mechanical perturbations (stretch; deep inspirations; etc.) [116] [117] [118] . It is becoming increasingly clear that this is related to a dynamic re-organization of the actin and myosin filaments during contraction. This adaptation of ASM to its microenvironment ('plasticity') may explain many lung/airway phenomena and offer clues for novel therapeutic intervention.
A major and fundamental limitation in studies aimed at better understanding and treating asthma has been the lack of a good animal model of asthma. Asthma is characterized, in part, by AHR, reversible bronchoconstriction, wheezing, inflammation, and cellular changes related to the muscle (hypertrophy and/or hyperplasia), epithelium (denudation; mucous production), and inflammatory cells (infiltration; degranulation; phenotypic changes). There are many animal models which feature a degree of AHR (e.g., induced by allergens or noxious agents) which may or may not be accompanied by inflammation, or which reproduce many features of airway inflammation without a change in ASM responsiveness. Regarding those studies which do find AHR in an experimental model, this is usually minor compared to that seen in asthmatics: there is generally only a modest increase in the maximal response and a slight leftward shift, compared to the dramatic shift of several log units in the human condition. Animals do not wheeze (although horses can manifest heaves). In summary, there is no animal model which reproduces fully all the features of asthma. Ultimately, our goal should be to better understand excitation-contraction coupling in human ASM, and changes in that coupling should be studied in tissues from asthmatics. 
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